Published in BMC Bioinformatics on October 21, 2014
CERAPP: Collaborative Estrogen Receptor Activity Prediction Project. Environ Health Perspect (2016) 0.87
A Rat α-Fetoprotein Binding Activity Prediction Model to Facilitate Assessment of the Endocrine Disruption Potential of Environmental Chemicals. Int J Environ Res Public Health (2016) 0.79
Pathway Analysis Revealed Potential Diverse Health Impacts of Flavonoids that Bind Estrogen Receptors. Int J Environ Res Public Health (2016) 0.75
Proceedings of the 2014 MidSouth Computational Biology and Bioinformatics Society (MCBIOS) Conference. BMC Bioinformatics (2014) 0.75
Discriminating agonist and antagonist ligands of the nuclear receptors using 3D-pharmacophores. J Cheminform (2016) 0.75
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev (2009) 9.60
Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem (2006) 8.75
Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov (2004) 8.10
Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature (1995) 6.33
Protein-ligand docking: current status and future challenges. Proteins (2006) 5.92
Benchmarking sets for molecular docking. J Med Chem (2006) 5.57
Nuclear hormone receptors and gene expression. Physiol Rev (2001) 4.56
Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem (2005) 3.71
A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environ Health Perspect (1995) 3.47
Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J (1999) 2.81
Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A (1998) 2.68
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol (2008) 2.44
The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci (2000) 2.42
Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol (2011) 2.28
Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect (2003) 2.27
Flexible protein-protein docking. Curr Opin Struct Biol (2006) 2.27
Nuclear hormone receptor targeted virtual screening. J Med Chem (2003) 2.05
Endocrine-disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol in vitro: new data and a brief review. Environ Health Perspect (2007) 1.95
Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol (2008) 1.89
Bisphenol A: Perinatal exposure and body weight. Mol Cell Endocrinol (2009) 1.82
Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med (2006) 1.80
The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol (2003) 1.63
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol (2003) 1.61
Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comput Aided Mol Des (2010) 1.48
Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Rep (2007) 1.47
Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol (2010) 1.38
Decision forest: combining the predictions of multiple independent decision tree models. J Chem Inf Comput Sci (2003) 1.32
Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts. Environ Health Perspect (2002) 1.31
Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes. Proc Natl Acad Sci U S A (2012) 1.26
Diethylstilbestrol usage: Its interesting past, important present, and questionable future. Med Clin North Am (1974) 1.26
Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol (2010) 1.25
Risk of breast cancer in women exposed to diethylstilbestrol in utero: prelimiinary results (United States). Cancer Causes Control (2002) 1.20
Response to A critique of the European Commission Document, "State of the Art Assessment of Endocrine Disrupters" by Rhomberg and colleagues--letter to the editor. Crit Rev Toxicol (2012) 1.20
Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J Biol Chem (2001) 1.15
Fetal death and maternal occupation. An analysis of birth records in the State of Washington. J Occup Med (1984) 1.13
Lessons learnt from structural studies of the oestrogen receptor. Best Pract Res Clin Endocrinol Metab (2006) 1.10
An integrated "4-phase" approach for setting endocrine disruption screening priorities--phase I and II predictions of estrogen receptor binding affinity. SAR QSAR Environ Res (2002) 1.10
Mold(2), molecular descriptors from 2D structures for chemoinformatics and toxicoinformatics. J Chem Inf Model (2008) 1.09
Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology. Reprod Toxicol (2013) 1.07
Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors. Proc Natl Acad Sci U S A (2012) 1.06
The EDKB: an established knowledge base for endocrine disrupting chemicals. BMC Bioinformatics (2010) 1.03
Flexible docking and design. Annu Rev Biophys Biomol Struct (1995) 0.97
Cancer risk in DES daughters. Cancer Causes Control (2010) 0.97
Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α. Nat Chem Biol (2013) 0.96
Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. Toxicol Appl Pharmacol (2013) 0.96
Tiered screening and testing strategy for xenoestrogens and antiandrogens. Toxicol Lett (1998) 0.95
Pathological semen and anatomical abnormalities of the genital tract in human male subjects exposed to diethylstilbestrol in utero. J Urol (1977) 0.95
EADB: an estrogenic activity database for assessing potential endocrine activity. Toxicol Sci (2013) 0.91
State of the science of endocrine disruptors. Environ Health Perspect (2013) 0.89
Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers. Bioorg Med Chem Lett (2005) 0.88
Structure of estradiol metal chelate and estrogen receptor complex: the basis for designing a new class of selective estrogen receptor modulators. J Med Chem (2011) 0.86
The endocrine system: an overview. Alcohol Health Res World (1998) 0.86
Endocrine-disrupting compounds: a review of their challenge to sustainable and safe water supply and water reuse. Environ Toxicol (2006) 0.85
Homology modeling, molecular docking, and molecular dynamics simulations elucidated α-fetoprotein binding modes. BMC Bioinformatics (2013) 0.85
CoMFA and docking study of novel estrogen receptor subtype selective ligands. J Comput Aided Mol Des (2003) 0.84
Comparative molecular field analysis (CoMFA) model using a large diverse set of natural, synthetic and environmental chemicals for binding to the androgen receptor. SAR QSAR Environ Res (2004) 0.84
Agrichemicals in Nebraska, USA, watersheds: occurrence and endocrine effects. Environ Toxicol Chem (2009) 0.84
Steroid signaling: ligand-binding promiscuity, molecular symmetry, and the need for gating. Steroids (2014) 0.81
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. J Mol Graph Model (2006) 0.81
Effects of environmental endocrine disruptors and phytoestrogens on the kisspeptin system. Adv Exp Med Biol (2013) 0.79
Diethylstilbestrol (DES) and breast cancer. Epidemiol Rev (1993) 0.78
Cervical and vaginal cancer detection at a regional diethylstilbestrol (DES) screening clinic. Cancer Detect Prev (1988) 0.77
A testing deadline for endocrine disrupters. Environ Sci Technol (1996) 0.76
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol (2006) 5.92
ISA software suite: supporting standards-compliant experimental annotation and enabling curation at the community level. Bioinformatics (2010) 5.60
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
Toward interoperable bioscience data. Nat Genet (2012) 4.72
The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15
Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics (2005) 3.93
A strategy capitalizing on synergies: the Reporting Structure for Biological Investigation (RSBI) working group. OMICS (2006) 3.51
ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ Health Perspect (2003) 3.39
QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn (2004) 2.73
Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol (2006) 2.59
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Development of public toxicogenomics software for microarray data management and analysis. Mutat Res (2004) 2.29
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology (2013) 2.02
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
Assessing batch effects of genotype calling algorithm BRLMM for the Affymetrix GeneChip Human Mapping 500 K array set using 270 HapMap samples. BMC Bioinformatics (2008) 1.98
GOFFA: gene ontology for functional analysis--a FDA gene ontology tool for analysis of genomic and proteomic data. BMC Bioinformatics (2006) 1.72
Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol (2007) 1.71
ArrayTrack: an FDA and public genomic tool. Methods Mol Biol (2009) 1.71
DNA microarrays are predictive of cancer prognosis: a re-evaluation. Clin Cancer Res (2010) 1.69
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol (2003) 1.61
Mining FDA drug labels using an unsupervised learning technique--topic modeling. BMC Bioinformatics (2011) 1.53
Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52. Altern Lab Anim (2005) 1.52
FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today (2011) 1.42
Comparing next-generation sequencing and microarray technologies in a toxicological study of the effects of aristolochic acid on rat kidneys. Chem Res Toxicol (2011) 1.41
Technical reproducibility of genotyping SNP arrays used in genome-wide association studies. PLoS One (2012) 1.36
Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn (2011) 1.33
Decision forest: combining the predictions of multiple independent decision tree models. J Chem Inf Comput Sci (2003) 1.32
Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts. Environ Health Perspect (2002) 1.31
SOAPsplice: Genome-Wide ab initio Detection of Splice Junctions from RNA-Seq Data. Front Genet (2011) 1.31
Phytoestrogens and mycoestrogens bind to the rat uterine estrogen receptor. J Nutr (2002) 1.27
Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study. PLoS Comput Biol (2011) 1.26
Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics (2005) 1.25
Investigating drug repositioning opportunities in FDA drug labels through topic modeling. BMC Bioinformatics (2012) 1.22
Multi-class cancer classification by total principal component regression (TPCR) using microarray gene expression data. Nucleic Acids Res (2005) 1.19
Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX (2013) 1.19
Assessment of prediction confidence and domain extrapolation of two structure-activity relationship models for predicting estrogen receptor binding activity. Environ Health Perspect (2004) 1.15
A decade of toxicogenomic research and its contribution to toxicological science. Toxicol Sci (2012) 1.14
SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res (2009) 1.10
Mold(2), molecular descriptors from 2D structures for chemoinformatics and toxicoinformatics. J Chem Inf Model (2008) 1.09
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov (2010) 1.08
Multi-class tumor classification by discriminant partial least squares using microarray gene expression data and assessment of classification models. Comput Biol Chem (2004) 1.07
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol (2011) 1.06
Identification of genes and pathways involved in kidney renal clear cell carcinoma. BMC Bioinformatics (2014) 1.05
Gene expression profile exploration of a large dataset on chronic fatigue syndrome. Pharmacogenomics (2006) 1.04
Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem (2003) 1.03
The EDKB: an established knowledge base for endocrine disrupting chemicals. BMC Bioinformatics (2010) 1.03
Chemical effects in biological systems--data dictionary (CEBS-DD): a compendium of terms for the capture and integration of biological study design description, conventional phenotypes, and 'omics data. Toxicol Sci (2005) 1.01
Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists. BMC Bioinformatics (2006) 0.98
Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use. Environ Health Perspect (2006) 0.98
An FDA bioinformatics tool for microbial genomics research on molecular characterization of bacterial foodborne pathogens using microarrays. BMC Bioinformatics (2010) 0.97
Three new consensus QSAR models for the prediction of Ames genotoxicity. Mutagenesis (2004) 0.96
Enhanced atherosclerosis in TIPE2-deficient mice is associated with increased macrophage responses to oxidized low-density lipoprotein. J Immunol (2013) 0.95
Toward a checklist for exchange and interpretation of data from a toxicology study. Toxicol Sci (2007) 0.95
Decision forest analysis of 61 single nucleotide polymorphisms in a case-control study of esophageal cancer; a novel method. BMC Bioinformatics (2005) 0.95
Integrating time-course microarray gene expression profiles with cytotoxicity for identification of biomarkers in primary rat hepatocytes exposed to cadmium. Bioinformatics (2005) 0.94
Spec2D: a structure elucidation system based on 1H NMR and H-H COSY spectra in organic chemistry. J Chem Inf Model (2006) 0.93
The liver toxicity biomarker study: phase I design and preliminary results. Toxicol Pathol (2009) 0.93
In silico drug repositioning: what we need to know. Drug Discov Today (2012) 0.93
Evaluation of gene expression data generated from expired Affymetrix GeneChip® microarrays using MAQC reference RNA samples. BMC Bioinformatics (2010) 0.92
Two new ArrayTrack libraries for personalized biomedical research. BMC Bioinformatics (2010) 0.92
Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol (2010) 0.92